Syngene International Ltd

BSE
SYNGENE •
BUY

1W Return

1M Return

6M Return

1Y Return

3Y Return

The current prices are delayed, login or open an account for live prices.
Start SIP in Syngene International Ltd
Stock Performance
52 Week Low - High
Today’s Low - High

Open

Prev. Close

Total Traded Value

View details of Market Depth
Fundamental

Market Cap (in crs)

Face Value

Turnover (in lacs)

Key Metrics
Qtr Change %
52W Low on Jun 04, 2024
5.8
TTM PE Ratio
Below industry Median
59.4
Price to Book Ratio
High in industry
7.1
Dividend yield 1yr %
Low in industry
0.2
TTM PEG Ratio
PEG TTM is much higher than 1
6
RSI
RSI is mid-range
69.4
MFI
MFI strongly Overbought
89

Syngene International Ltd Key Financials

View more

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

*All values are in ₹ Cr.

Syngene International Ltd shareholding Pattern

Promoter
54.8%
Foreign Institutions
20.9%
Mutual Funds
12.6%
Domestic Institutions
15.8%
Public
8.2%
Promoter
54.8%
Foreign Institutions
21.2%
Mutual Funds
11.9%
Domestic Institutions
14.6%
Public
9.1%
Promoter
54.8%
Foreign Institutions
23.6%
Mutual Funds
9.1%
Domestic Institutions
11.7%
Public
9.5%
Promoter
54.8%
Foreign Institutions
23.2%
Mutual Funds
8.6%
Domestic Institutions
11.2%
Public
10.2%
Promoter
54.9%
Foreign Institutions
23.3%
Mutual Funds
8.4%
Domestic Institutions
10.7%
Public
10.6%
Promoter
64.9%
Foreign Institutions
16.9%
Mutual Funds
5%
Domestic Institutions
7%
Public
10.8%

Syngene International Ltd Technical Analysis

Moving Averages Analysis
Moving Averages Analysis
Current Price
Bullish Moving Averages
16
Bearish Moving Averages
0
5Day EMA
743.30
10Day EMA
736.00
12Day EMA
733.50
20Day EMA
725.30
26Day EMA
720.60
50Day EMA
711.00
100Day EMA
708.80
200Day EMA
709.30
5Day SMA
743.90
10Day SMA
735.10
20Day SMA
723.00
30Day SMA
713.10
50Day SMA
699.00
100Day SMA
702.80
150Day SMA
708.20
200Day SMA
715.60
Delivery & Volume
Resistance & Support
749.33
Pivot
Resistance
First Resistance
756.17
Second Resistance
760.33
Third Resistance
767.17
Support
First Support
745.17
Second support
738.33
Third Support
734.17
Relative Strength Index
69.40
Money Flow Index
88.96
MACD
12.88
MACD Signal
10.57
Average True Range
15.50
Average Directional Index
25.13
Rate of Change (21)
6.36
Rate of Change (125)
2.75
Peer comparison
Compare
Company
Market Price
Market Cap
52W Low
52W High
Ajanta Pharma Ltd.
27993.38
1391
2531.95
Glenmark Pharmaceuticals Ltd.
39802.64
695.55
1426.7
Ipca Laboratories Ltd.
30901.17
765.05
1373.95
J B Chemicals & Pharmaceuticals Ltd.
27928.26
1185
1935
Gland Pharma Ltd.
33829.3
1137.3
2195.75
Emcure Pharmaceuticals Ltd.
25856.36
1325.05
1408

Syngene International Ltd Company background

Founded in: 1993
Managing director: Jonathan Hunt
Syngene International Limited is an integrated research, development and manufacturing services organization serving global pharmaceutical, biotechnology, nutrition, animal health, consumer goods and specialty chemical sectors. Headquartered in India, the operations are driven by its highly qualified teams comprising 6000 scientists and its stateoftheart facilities, spread over 2.2 million sq. ft., across 3 locations in India: Bangalore, Hyderabad and Mangalore. The Company operate into 4 business divisions comprising of Discovery Services, Development Services, Manufacturing Services and the Dedicated Centers.The Company was promoted by Biocon and Kiran Mazumdar Shaw, a promoter of Biocon Limited. The Companys healthrelated services extend across all major therapeutic areas and modalities. It provides endtoend services within the Contract Research Organization (CRO) and a growing range of services within the Contract Development and Manufacturing Organization (CDMO). The primary target market for these services is the pharmaceutical and biotechnology (biotech) sectors. The same scientific capabilities that serve human health also serve nutrition, animal health, consumer goods, agrichemicals, and specialty chemical sectors.Syngene International Limited was incorporated at Bangalore in the year 1993. During the year 19941995, the company pioneered in CRO services for both Chemistry and Biology. During the year 20012002, the company acquired a new facility inclusive of a cGMP pilot plant. In March 30, 2002, the companys 99.9% equity share was transferred to Biocon and the company became a subsidiary of Biocon Ltd. During the year 20032004, the company introduced Process Research and Optimization Services. In October 21, 2004, the company commissioned a new research facility at Boammasandra, Bangalore. In February 15, 2006, the company commissioned new facility at Biocon Park. In August 30, 2006, the company received approval of additional facility to set up as SEZ unit from Cochin Special Economic Zone. During the year 20062007, Bristol Myers Squibb had entered into a long term agreement with the company to set up an exclusive research facility to house more than 400 scientists. During the year, the company had ventured into other area of Biology viz Genetic Engineering, Protein Chemistry, and assay development. The company had developed extensive expertise in the creation of customized stable cell lines expressing proteins / receptors of intersest. During the year 20072008, the company entered a long term service agreement with BMS. During the year 20082009, the company created an alliance partnership with DuPont Crop Protection.On 21 July 2011, Syngene International and Endo Pharmaceuticals USA announced that they have signed an agreement to expand their collaboration to develop novel biological therapeutic molecules against cancer. Syngene and Endo will partner on two new discovery programmes, strengthening their ongoing alliance in cancer research. Under the agreement, Endo will retain all rights to the molecules developed, while Syngene International will receive research fees, milestone payments and success fees from Endo.On 4 June 2012, Abbott, one of Indias largest healthcare companies, inaugurated its first nutrition research and development center in the country, in collaboration with Syngene International. The stateoftheart Research and Development center will focus on the development of sciencebased, affordable nutrition products for the country and enable the expansion of Abbotts nutrition product portfolio.In 2012, Syngene International received ANVISA Certification of clinical facilities. During the year under review, Syngene International acquired 100% stake in Clinigene International Limited from Biocon.Syngene International crossed an annual turnover of Rs 500 crore crore in the year ended 31 March 2013.In 2013, Baxter International Inc. collaborated with Syngene International to establish the Baxter Global Research Center. During the year under review, Syngene Internationals Control Testing Laboratory received acceptance from the Department of Health Human Services, US Food and Drug Administration.On 3 June 2014, BristolMyers Squibb and Syngene International announced a fiveyear extension of their drug discovery and development collaboration in India. Financial terms were not disclosed.In 2014, Syngene Internationals API manufacturing facility received acceptance from Department of Health Human Services, US Food and Drug Administration. During the year under review, Syngene International established a 75,000 sq. ft. centre to provide stability and analytical services.Syngene International made its debut on the secondary equity market on 11 August 2015. The stock debuted at Rs 295 on BSE, a premium of 18% compared to the initial public offer (IPO) price of Rs 250 per share. The Rs 550crore Initial Public Offering (IPO) through offer for sale from its parent Biocon Ltd. received an excellent response from investors and was subscribed 32.05 times. The issue opened for subscription on 27 July 2015 and closed on 29 July 2015.In 2015, Syngene Internationals subsidiary Clinigene International Limited, which provides clinical research and clinical trial services, was amalgamated with Syngene International. Syngene International crossed annual turnover of Rs 1000 crore in the year ended 31 March 2016.On 6 September 2016, Syngene International announced the establishment in Bangalore, India, of an integrated, multidisciplinary drug discovery and development center for Amgen, Inc. The stateoftheart dedicated center will be staffed by a team of more than 100 highly qualified Syngene scientists, working in close association with Amgen researchers around the world on the discovery and development of innovative medicines. In addition to being customized to meet Amgens functional requirements, the facility complies with the highest regulatory standards. Its design includes a range of environmentallyfriendly features and flexible layouts, and is configured to minimize solvent and effluent waste with a strong emphasis on laboratory safety and green chemistry.On 21 September 2016, Syngene International Ltd.and Strand Life Sciences announced that they have completed a deal through which Syngene has purchased assets of Strand Life Sciences related to systems biology, Heptox and pharma bioinformatics services. This includes target dossier business and rights to NGS data analytics and Sarchitect platforms, supported by a strong scientific team. Financial details of the deal were not disclosed. This deal gives Syngene access to Strands patented Virtual Liver model and the NGS analytics platform. The Virtual Liver model is able to predict the toxic effect of different drugs or chemicals on the liver (both rat and human) using information from laboratorybased experiments prior to actual testing on live animals or humans. Strand NGS is an integrated platform that provides analysis, management and visualization tools for nextgeneration sequencing data.On 2 March 2017, Herbalife, a global nutrition company, announced the launch of its first Nutrition Research and Development Lab in India, in partnership with Syngene International. The strategic partnership will help Herbalife Nutrition develop and formulate worldclass nutrition products for Indian consumers.On 27 July 2017, Syngene International announced the expansion of its research collaboration with Amgen Inc. As a result, Syngene will expand the Syngene Amgen Research Development Center (SARC) in terms of size and scope of its operations. The expansion of SARC will be customized to meet Amgens functional requirements and will include a range of environmentfriendly features that will enable optimal utilization of the laboratory space.On 14 November 2017, Syngene International announced that it has expanded its ongoing collaboration with BristolMyers Squibb. The next phase of the partnership will see the addition of a new facility to support future BristolMyers Squibb research and development operations, an expansion of the team and the extension of the existing agreement through 2026. As part of the expansion, Syngene will set up a new dedicated facility spread across 25,000 sq. ft. of laboratory and office space for BristolMyers Squibb. This facility will house an additional team of 75 Syngene scientists who will work exclusively in support of BristolMyers Squibb.On 26 March 2018, Syngene International announced an RD agreement with GSK, a scienceled global healthcare company. The multiyear agreement will focus on accelerating the discovery of new drug candidates using Syngenes discovery services platforms. As part of the agreement, Syngene will setup a customized discovery research laboratory to support projects across several therapeutic areas. A team of Syngene scientists will work closely with GSKs global RD teams on discovery research projects to identify new drug candidates with the potential to address some of the worlds most pressing healthcare needs.On 30 May 2018, Syngene International announced that the company has entered into a nonexclusive partnering agreement with Zumutor Biologics, an emerging immunooncology company, to access Zumutors proprietary human phage/yeast display library. This collaboration further enhances Syngenes marketleading capabilities in Discovery Biology, providing its scientists with additional tools to help solve complex biology problems in biotherapeutic drug discovery. Under the terms of the agreement, Syngene will screen target antigens against Zumutors proprietary human antibody libraries to identify and characterize novel antibody clones, which will be further developed by Syngene towards novel biotherapeutics programs for its partnersDuring year 201819, the Company commissioned Phase I of its upgraded S2 facility, which brings on board 105,000 sq. ft of space. The Companys Dedicated RD Centres gained from the extension of the multiyear agreement up to 2024 with Baxter Healthcare Corporation, a global healthcare company. In line with the revised agreement, a new laboratory was commissioned, and the strength of the scientific team supporting Baxter was increased. In line with the contract expansion and extension with BristolMyers Squibb (BMS), a multinational pharmaceutical company, Syngene commissioned a new research facility spread across 25,000 sq. ft. of laboratory and office space during the year. The Amgen dedicated centre houses around 75 Syngene scientists. The Company completed the development and clinical supplies manufacturing of a drug product for Amgen. The Companys research collaboration with GSK, signed in FY18, became operational during the year. In year 201920, the Company developed and validated a Human Papilloma Virus (HPV) assay, a test system increasingly being used for cervical cancer screening. During year 202021, the Company commissioned the first phase of new RD centre in Hyderabad. It commenced API manufacturing facility in Mangaluru and expanded the RD facility in Bengaluru. Two 2KL bioreactors were commissioned during the year and a microbial manufacturing facility was set up, to strengthen biologics manufacturing capacity. During year 202122, the Company expanded its research facilities in Bangalore and Hyderabad. As part of the third phaseof expansion, capacity for 300 scientists was added in Hyderabad, taking the total capacity to around 600 scientists. It also invested in enhancing its scientific capabilities to both sustain as a service provider for fully integrated therapeutic discovery. The Research Informatics unit launched a drug discovery informatics platform to empower the scientists with project information and tools to generate and evaluate hypotheses. The Company signed a fiveyear agreement with IAVI1 , a USAbased, nonprofit, scientific research organization to develop and manufacture three recombinant, monoclonal antibodies (mAbs) for Human Immunodeficiency Virus (HIV). A cGMP microbial manufacturing facility with 500liter capacity was commissioned in 2021. A fourth additional 2,000liter singleuse bioreactor was introduced to the mammalian biologics facility. During the year 202223, Syngenes second campus in Discovery Chemistry operations in Hyderabad grew to over 900 scientists. It commissioned a new PROTAC lab in Hyderabad commissioned a kilo lab to expedite formulation and process development work and a stateoftheart sterile FillFinish facility for smallscale clinical manufacturing commissioned the advancement of Amgens RD projects.In FY23, the Company launched new differentiated platforms such as SynTACs (targeted degradation), SARchitect (data analysis and virtual collaboration), and SynTIPS (data analysis related to biological targets and pathways). Additionally, existing platforms, Syn.AI (AIenhanced therapeutic RD) and SynVent (integrated drug discovery), were enhanced further. The construction of a stateoftheart, fillfinish facility for sterile injectable drugs was commissioned. The commercial manufacturing of drug substance for Zoetis was started. In addition to growing capabilities in monoclonal antibodies, the portfolio expanded for GMP manufacturing of plasmid DNA and mRNA.
Read More

Syngene International Ltd FAQs

The past 1-year return of Syngene International Ltd [SYNGENE] share was -3.31. The Syngene International Ltd [SYNGENE] share hit a 1-year low of Rs. 608 and a 1-year high of Rs. 860.2.

The Mutual Fund Shareholding was 12.59% at the end of .

You can easily buy Syngene International Ltd shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.

Open Demat Account
+91 -

personImage
Open Demat Account
+91 -